Team

Brook Byers
Partner, Kleiner Perkins Caufield & Byers (KPCB)

Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors.

He is currently on the Board of Directors of nine companies, most recently joining CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, Pacific Biosciences, Inc., Tethys and XDx, Inc. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Hybritech (Chairman), Genprobe and others. These companies have pioneered the medical use of molecular biology, monoclonal antibodies, molecular diagnostics and genomics.

Brook was President and a Director of the Western Association of Venture Capitalists. He is currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford’s Bio-X Advisory Council, the Stanford Eye Council and TechNet. He was Co-Chair of the five year, $1.4 billion, UCSF Capital Campaign. He received the Distinguished Citizen Award in Life Science from the Commonwealth Club of California in 2006. In 2007, he was awarded the “UCSF Medal” as their honorary degree equivalent. He earned a BS in electrical engineering from Georgia Tech and an MBA from Stanford University.